Education
About Us
Working with TipRanks
Follow Us
Quince Therapeutics (QNCX)
NASDAQ:QNCX
Total Valuation
Quince Therapeutics has a market cap or net worth of $44.88M. The enterprise value is $56.09M.
Market Cap$44.88M
Enterprise Value$56.09M
Share Statistics
Quince Therapeutics has 44.09M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44.09M
Owened by Insiders18.09%
Owened by Instutions3.83%
Financial Efficiency
Quince Therapeutics’s return on equity (ROE) is -1.89 and return on invested capital (ROIC) is -53.31%.
Return on Equity (ROE)-188.51%
Return on Assets (ROA)-49.64%
Return on Invested Capital (ROIC)-53.31%
Return on Capital Employed (ROCE)-53.44%
Revenue Per Employee$4,666.667
Profits Per Employee-$1,578,555.556
Employee Count36
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Quince Therapeutics is -1.42. Quince Therapeutics’s PEG ratio is -0.03.
PE Ratio-1.42
PS Ratio0.00
PB Ratio2.68
Price to Fair Value2.68
Price to FCF-2.52
Price to Operating Cash Flow-2.54
PEG Ratio-0.03
Income Statement
In the last 12 months, Quince Therapeutics had revenue of $168.00K and earned -$56.83M in profits. Earnings per share was -$1.32.
Revenue$168.00K
Gross Profit$0.00
Operating Income-$52.24M
Pretax Income-$56.74M
Net Income-$56.83M
EBITDA-35.98M
Earnings Per Share (EPS)-1.32
Cash Flow
In the last 12 months, operating cash flow was -$31.90M and capital expenditures -$257.00K, giving a free cash flow of -$32.16M billion.
Operating Cash Flow-$31.90M
Free Cash Flow-$32.16M
Free Cash Flow per Share-$0.73
Dividends & Yields
Quince Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-39.75%
Earnings Yield-70.24%
Stock Price Statistics
Beta0.21
52-Week Price Change7.45%
50-Day Moving Average1.40
200-Day Moving Average1.23
Relative Strength Index (RSI)36.92
Average Volume (3m)137.37K
Important Dates
Quince Therapeutics upcoming earnings date is Aug 12, 2025, Before Open.
Last Earnings DateMar 24, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Quince Therapeutics as a current ratio of 6.05, with Debt / Equity ratio of 0.49
Current Ratio6.05
Quick Ratio6.05
Debt to Market Cap0.18
Net Debt to EBITDA-0.15
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Quince Therapeutics has paid $87.00K in taxes.
Income Tax$87.00K
Effective Tax Rate0.15%
Enterprise Valuation
Quince Therapeutics EV to EBITDA ratio is -1.56, with an EV/FCF ratio of -2.78.
EV to Sales0.00
EV to EBITDA-1.56
EV to Free Cash Flow-2.78
EV to Operating Cash Flow-2.81
Balance Sheet
Quince Therapeutics has $40.78M in cash and marketable securities with $14.81M in debt, giving a net cash position of -$25.97M billion.
Cash & Marketable Securities$40.78M
Total Debt$14.81M
Net Cash-$25.97M
Net Cash Per Share-$0.59
Tangible Book Value Per Share-$0.69
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Quince Therapeutics is $6.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.67
Price Target Upside560.40%
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast
EPS Growth Forecast-55.81%